Deerland granted patent for Bacillus subtilis probiotic

7-Jan-2022

The patent summarises studies of 30, 60 and 90 days in individuals with bowel irregularity who consumed B. subtilis, all resulting in measurable improvements

Deerland Probiotics & Enzymes, a supplier of products for microbiome health, has announced the United States Patent and Trademark Office has published its application for a distinct use of its signature strain DE111 of the probiotic species, Bacillus subtilis based on compelling human clinical trials.

The patent application (US# 2021-315808 A1) titled “Bacillus subtilis containing composition for treatment of gastrointestinal irregularity,” claims the use of strain DE111 for promoting GI and bowel regularity.

The application, in part, describes, “As a component of the human microbiome, Bacillus subtilis may potentially have the ability to promote gastrointestinal health, including helping its host in digestion, making Bacillus subtilis a good candidate for probiotic compositions.”

The application summarises studies of 30, 60 and 90 days in individuals with bowel irregularity who consumed B. subtilis, all resulting in measurable improvements. According to the application's summary of invention, “the present disclosure relates to a method of [supporting] gastrointestinal irregularity in an individual, wherein the individuals has at least one 24-hour episode per month of bowel movements measuring 1 or 2 on the Bristol Stool Scale.”

Bacillus subtillis is a spore-forming probiotic, which has the ability to protect itself through manufacturing and through digestion. B. subtilis DE111 has more than 30 studies (in vitro and human clinicals) demonstrating its effects on digestive and immune health in adults and children.

Sign up for your free email newsletter

“This patent application underscores the safety and efficacy of B. subtilis, including DE111,” said Dr John Deaton, VP of Science and Technology at Deerland. “And it is timely, as according to Allied Market Research, worldwide, bowel irregularity is a common occurrence in up to 32.5% of the global population; and further, bowel irregularity and the discomfort it causes increases with age.”

Companies